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Background: The impact of HIV stigma on viral suppression
among people living with HIV (PLHIV) is not well characterized.
Setting: Twenty-one communities in Zambia and South Africa,
nested within the HPTN 071 (PopART) trial.
Methods: We analyzed data on viral suppression (,400 copies
HIV RNA/mL) among 5662 laboratory-confirmed PLHIV aged
18–44 years who were randomly sampled within the PopART trial
population cohort 24 months after enrolment (PC24). We collected
data on experiences and internalization of stigma from those PLHIV
who self-reported their HIV status (n = 3963/5662) and data on
perceptions of stigma from a 20% random sample of all PLHIV (n =
1154/5662). We also measured stigma at the community-level
among PLHIV, community members, and health workers. We
analyzed the association between individual- and community-level
measures of HIV stigma and viral suppression among PLHIV,
adjusting for confounding.
Results: Of all 5662 PLHIV, 69.1% were virally suppressed at
PC24. Viral suppression was highest among those 3963 cohort
participants who self-reported living with HIV and were on ART
(88.3%), and lower among those not on treatment (37.5%). Self-
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identifying PLHIV who reported internalized stigma were less likely
to be virally suppressed (75.0%) than those who did not (80.7%;
adjusted risk ratio, 0.94 95% CI: 0.89 to 0.98). Experiences,
perceptions, and community-level measures of stigma were not
associated with viral suppression.
Conclusion: Internalized stigma among PLHIV was associated
with a lower level of viral suppression; other dimensions of stigma
were not. Stigma reduction approaches that address internalized
stigma should be an integral component of efforts to control the
HIV epidemic.
Key Words: HIV stigma, viral suppression, PLHIV, community
members, health workers
(J Acquir Immune Defic Syndr 2020;85:561–570)
INTRODUCTION
Increasing the proportion of people living with HIV
(PLHIV) who are virally suppressed is critical.1 UNAIDS
90:90:90 targets reflect the cascade steps needed to achieve
this: diagnosis of PLHIV, rapid initiation of antiretroviral
treatment (ART), and adherence to treatment to sustain viral
suppression. Although most sub-Saharan African countries
have implemented “treat all” policies, under which PLHIV
are offered ART regardless of CD4 count, progress is
suboptimal. In 2019, UNAIDS estimated that viral suppres-
sion among PLHIV was 92% in eSwatini, 72% in Malawi,
69% in Tanzania, and 77% in Zambia. In South Africa, only
64% of all PLHIV are virally suppressed,2 the country
accounting for approximately 20% of the global burden.
We hypothesize that HIV stigma may act as a barrier to
PLHIV achieving viral suppression and that this effect may
arise because stigma can reduce PLHIV being diagnosed
quickly, slow the rate at which PLHIV start treatment, and/or
impede antiretroviral medication adherence and attendance
for follow-up ART collections and retention in care. Access
to HIV testing has been constrained by stigma among men
who have sex with men in high-income settings,3 and among
the general population in low-income settings,4,5 because
clients feel shame in accessing testing, anticipate being
stigmatized when accessing services,6 or want to avoid being
associated with HIV. For similar reasons, stigma acts as a
barrier to PLHIV accessing care in the United States,7 among
pregnant women who test positive in antenatal settings in
Africa,8 and more generally in low- and middle-income
settings.9 Adherence to antiretroviral medication is lower in
the presence of stigma among young people in the United
States10 and globally11 because stigma negatively affects
mental health and prevents PLHIV from disclosing their
status to others and accessing psychosocial support.6
We therefore investigated the association between HIV
stigma and viral suppression among a large, representative
sample of PLHIV in the 21 communities participating in the
HPTN 071 (PopART) trial in Zambia and South Africa.12,13 At
24 months (PC24), we assessed (1) whether PLHIV who
reported experienced, internalized, or perceived stigma had
lower rates of viral suppression, (2) whether PLHIV living in
communities with higher levels of stigma had lower rates of
viral suppression among PLHIV, and, (3) whether associations
differed between the arms of the trial, which delivered different
approaches to HIV testing and treatment. We focused on viral
suppression as our primary outcome and hypothesized that
stigma would reduce viral suppression as a result of the
negative effect of stigma on each step in the HIV-care cascade.
Thus, we show associations between stigma and self-reported
(SR) treatment access and adherence as supporting analyses.
METHODS
Setting
The HPTN 071 (PopART) trial was a 3-arm cluster
randomized trial conducted between 2013 and 2018 in 21
urban/periurban study communities (12 in Zambia and 9 in
Western Cape Province, South Africa).12,14 Study communities
were arranged in 7 triplets matched on geographical location
and estimated HIV prevalence. Study communities in each
triplet were randomly allocated to 3 study arms. In the 2
treatment arms (A and B), a new cadre of community-based
health workers (HWs) known as Community HIV care
Providers (CHiPs) carried out door-to-door HIV testing and
referral services. In arm A, ART was offered to PLHIV
regardless of CD4 count from the start of the trial; in arms B
and C, ART was offered according to national guidelines,
which changed over the course of the trial and became
regardless of CD4 count in 2016. At PC24, viral suppression
among PLHIV was higher, and HIV incidence was 20% lower
in arms A and B than in arm C.12 In all arms, health facility-
based and existing community-based HWs received training on
the study aims but did not receive specific antistigma training.
Outcome Study Population
The main study population for this analysis was PLHIV
recruited within a population-based cohort (PC). In each
community, 1 randomly selected adult aged 18–44 years was
selected from each of a random sample of households.
Enrolment mostly occurred between December 2013 and
March 2015, although some additional participants were
enrolled later in some communities. PC participants were
surveyed at baseline (PC0) and at 12, 24, and 36 months
(PC12/PC24/PC36; no data from PC36 were used in this
analysis). Blood samples were drawn, and HIV viral load
testing was performed on all laboratory-confirmed HIV-
positive participants at PC24.
For this analysis, we excluded individuals with missing
data on viral load, critical sociodemographic factors, SR HIV
status, testing and treatment history, or HIV stigma at PC24,
such that laboratory-confirmed HIV-positive 5662 partici-
pants were included (see Figure 1, Supplemental Digital
Content, http://links.lww.com/QAI/B538). We refer to this
group as PC-HIV+ throughout the article. The 571 individ-
uals (9.2%) who had incomplete data showed no significant
differences in sex, age, or viral suppression from the 5662
PC-HIV+ participants (see Table 1, Supplemental Digital
Content, http://links.lww.com/QAI/B538).
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Questions on experienced and internalized stigma could
only be asked of participants who SR living with HIV (n =
3963). We refer to this sub-group as PC-HIV+SR. Addition-
ally, a 20% subsample of all PC-HIV+ participants (regard-
less of SR HIV status) were randomly selected to answer
additional questions on perceived stigma (n = 1154). We refer
to this subgroup as PC-HIV+sub.
Blood samples were analyzed in-country using a
single fourth-generation assay (Architect HIV Ag/Ab
Combo Assay; Abbott Diagnostics, Delkenheim, Germany).
Further testing was performed at the HPTN Laboratory
Center (Johns Hopkins University, Baltimore, MD). Sam-
ples that had reactive results in-country were tested with a
second fourth-generation assay (GS HIV Combo Assay;
Bio-Rad Laboratories, Redmond, WA). HIV viral load
testing was performed at the HPTN Laboratory Center
(assay cut-off 400 copies/mL) for all PC-HIV+ participants
at PC24 to determine their viral suppression status (not
virally suppressed/virally suppressed), and we used this
binary variable as our outcome for analysis.
Measurement of Stigma Exposures
For individual-level stigma exposures among PC-
HIV+SR, we used 4 measures reflecting experienced stigma
in the community (combining 5 items), experienced stigma in
health service settings (3 items), internalized stigma (3 items),
and a combined measure of any type of stigma (11 items).15
Among PC-HIV+sub, we used 2 measures reflecting perceived
stigma in the community (5 items) and perceived stigma in
health service settings (2 items). Item wording is presented in
Table 1. All measures used in the study had been previously
validated, and Cronbach alpha and other measurement details
for each measure are shown in Table 2, Supplemental Digital
Content, http://links.lww.com/QAI/B538.15
TABLE 1. Description of Stigma Exposure Variables
Population Group and Exposure Stigma Items/Statements
PC-HIV+SR
Any reported internalized stigma (3 items) (1) I have lost respect or standing in the community because of my HIV status, (2) I think less
of myself because of my HIV status, (3) I have felt ashamed because of my HIV status
Any reported experienced stigma in the community (5
items)
(1) People have talked badly about me because of my HIV status, (2) someone else disclosed
my HIV status without my permission, (3) I have been verbally insulted, harassed, and/or
threatened because of my HIV status, (4) I have been physically assaulted because of my
HIV status, (5) I have felt that people have not wanted to sit next to me, eg, on public
transport, at church, or in a waiting room because of my HIV status
Any reported experienced stigma in health service
settings (3 items)
(1) I have been denied health services because of my HIV status, (2) healthcare workers talked
badly about me because of my HIV status, (3) a health worker disclosed my HIV status
without my permission
Any stigma (11 items) All items above
PC-HIV2 and PC-HIV+
Any negative attitudes (fear and judgment using 3
items)
(1) I fear that I could contract HIV if I come into contact with the saliva of a person living with
HIV, (2) I would not like to sit close to someone living with HIV, eg, on public transport, at
church, or in a waiting room, (3) I would be ashamed if someone in my family had HIV
PC-HIV2 only
Any perceived stigma in community settings (5 items) (1) People thought to be living with HIV are sometimes physically assaulted, (2) people
sometimes talk badly about PLHIV to others, (3) people thought to be living with HIV lose
respect or standing, (4) people thought to be living with HIV are verbally insulted, harassed
and/or threatened, (5) people sometimes disclose that other people are HIV positive without
their permission
Any perceived stigma in health service settings (2
items)
(1) Health workers sometimes talk badly about people living with or thought to be living with
HIV to others, (2) health workers sometimes disclose that other people are HIV positive
without their permission
HW and CHiPs
Any negative attitudes (fear and judgment using 5
items)
(1) I fear that I could contract HIV if I come into contact with the saliva of a person living with
HIV, (2) I avoid physical contact with clients living with HIV, (3) HIV is punishment from
God, (4) other people deserve access to health services more than PLHIV, (5) I would be
ashamed if someone in my family had HIV
HW-HIV- only
Any perceived stigma in the community (5 items) (1) People thought to be living with HIV are sometimes physically assaulted, (2) people
sometimes talk badly about PLHIV to others, (3) people thought to be living with HIV lose
respect or standing, (4) people thought to be living with HIV are verbally insulted, harassed,
or threatened, (5) people hesitate to start ARV drugs because they are afraid others will learn
they are living with HIV
Any perceived coworker stigma (4 items) (1) My coworkers sometimes talk badly about people thought to be living with HIV, (2) my
coworkers sometimes gossip about clients’ HIV test results, (3) my coworkers sometimes
treat PLHIV poorly when providing them with health services, (4) my coworkers sometimes
verbally insult clients living with HIV
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In addition to individual-level analysis, we also developed
community-level measures of stigma. To create these measures,
we used data from 2 further study populations. First, in each
community, we recruited a random 20% of PC participants who
did not self-report living with HIV and were confirmed as tested
HIV negative. We refer to this population as PC-HIV2. Data
from this group were used to characterize the communities (n =
4339 at PC24). We developed 3 stigma measures reflecting
average levels of fear and judgment (3 items), perceived stigma
in the community (5 items), and perceived stigma in the health
service setting (2 items). Community-level scores had a
theoretical range from 0 to 3 such that, for example, a mean
score of 1 indicated that people in that community on average
responded “disagree” to stigma items and a mean score of 2
indicates people who on average responded “agree.” Details of
the item wording and other measurement details are shown in
Table 1 and Table 2, Supplemental Digital Content, http://links.
lww.com/QAI/B538.
Second, we collected data from HWs, including the
study-specific CHiPs workers in arms A and B, in a separate
cohort study. Participants included CHiPs and HWs (in all
trial Arms) who were enrolled between July 2014 and May
2015 [round 1 (R1)].13 CHiPs were eligible for the study
upon recruitment to the PopART intervention team. HWs
included doctors, nurses, laboratory technicians, cleaners, and
security guards and community workers who worked within
community HIV services on a regular (at least biweekly)
basis. CHiPs and HWs were followed up in 2 rounds (R2
between June 2015 to June 2016 and R3 between January
2017 and February 2018).16 We generated community-level
measures of stigma among HWs, using the same approach
described above, reflecting the level of fear and judgment of
PLHIV by CHIPs and HWs (including only data from those
not self-reporting living with HIV, n = 516 and 1533,
respectively, in R3) and perceptions of stigma in the
community and by coworkers in the health facilities (includ-
ing all individuals regardless of HIV status, n = 635 and 1802,
respectively, in R3). Finally, for PC-HIV+SR, we also
summarized the indicators used in individual analysis at the
community level.
Statistical Analysis
First, we described the study population of PC-HIV+,
comparing characteristics between countries. We explored
associations between stigma domains, as we had previously
done at baseline.17
Second, we analyzed the association between socio-
demographic, HIV testing and treatment characteristics, and
viral suppression at PC24. We calculated risk ratios using
modified Poisson regression with robust standard errors,
adjusting for age, sex, and study community.
Third, we analyzed the individual-level association
between HIV stigma measured among PC-HIV+SR and
PC-HIV+sub and viral suppression at PC24, again calculating
risk ratios adjusted for age, sex, and study community. We
also calculated “fully” adjusted risk ratios using the same
approach and additionally adjusting for marital status,
education, and time of diagnosis (defined with 3 categories:
before PopART, during PopART, and missing date).
Fourth, using interaction tests, we explored whether the
strength of these associations differed by arm of the study.
Fifth, we produced cluster-level scatter plots to illus-
trate the strength of association between community-level
measures of stigma, measured at either PC24 or round 3 of the
health worker study, and the proportion of all PC-HIV+ who
were virally suppressed at PC24. To quantify the strength of
these associations, we used simple linear regression, weighted
by the sample size in each community, and reported the P
value for these associations.
Finally, in supplementary exploratory analyses, we
recalculated both the individual-level and community-level
stigma exposure variables using data from earlier rounds
(PC0, PC12, and the health worker surveys at R1 and R2).
We assessed whether there was evidence that the associa-
tion between stigma and viral suppression at PC24 was
similar using exposure measures from these earlier time
points. In addition, we characterized internalized stigma as
a continuous measure to assess whether the associations we
identified were similar to our primary analysis where
internalized stigma was included as a binary variable. We
further report the association between internalized stigma
and SR variables on the causal pathway to viral suppres-
sion: ever and currently taking ART, hiding pills, and
ART adherence.
Ethical Considerations
Ethical approval for all study procedures was obtained
from the institutional review boards of the London School of
Hygiene and Tropical Medicine, Stellenbosch University, and
the University of Zambia. All participants provided written
informed consent before enrolment.
RESULTS
The 5662 PC-HIV+ participants were predominantly
women (86.0%) and more were from Zambia (n = 3491)
than South Africa (n = 2171) (Table 2). More participants
had completed secondary education and were unmarried in
South Africa than in Zambia. At PC24, only 4.4% of
participants SR never having tested for HIV. However,
9.8% said that they did not know their current HIV status,
and 15.9% SR that their status was HIV negative, with both
figures higher in South Africa than in Zambia. Overall,
70.0% of PC-HIV+ reported that they knew their HIV-
positive status, and of these, the majority reported that they
were currently taking ART (63.0% of all PC-HIV+ in
Zambia, 50.6% in South Africa); 69.1% of all PC-HIV+
had viral suppression.
Of PC-HIV+SR, 30.3% reported having experienced
any stigma, and this was higher in Zambia (34.3%) than in
South Africa (23.0%). Stigma experienced in the community
was the most common form (20.7%), followed by internal-
ized stigma (16.0%) and stigma in a health setting (5.3%).
Similar to our findings at baseline, most of those who
reported stigma in a health setting also reported experiencing
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TABLE 2. Characteristics of PC-HIV+ With Viral Suppression Data at PC24 in 21 Communities in Zambia and South Africa
(n = 5662)
Categories
Zambia South Africa Total
N % N % N %
Sociodemographics
Sex Male 500 14.3 291 13.4 791 14.0
Female 2991 85.7 1880 86.6 4871 86.0
Age groups, yr 18–24 732 21.0 373 17.2 1105 19.5
25–34 1515 43.4 1012 46.6 2527 44.6
35–44 1244 35.6 786 36.2 2030 35.9
Education groups Did not complete secondary 1522 43.6 340 15.7 1862 32.9
Completed secondary 1803 51.6 1757 80.9 3560 62.9
Further 166 4.8 74 3.4 240 4.2
Marital status Married 2092 59.9 713 32.8 2805 49.5
Never married 421 12.1 1334 61.4 1755 31.0
Divorced/separated 671 19.2 96 4.4 767 13.5
Widowed 307 8.8 28 1.3 335 5.9
Study arm Arm A 1194 34.2 709 32.7 1903 33.6
Arm B 1094 31.3 655 30.2 1749 30.9
Arm C 1203 34.5 807 37.2 2010 35.5
Categories
Zambia South Africa Total
N % N % N %
Test and Treatment Status
Viral suppression status Not suppressed 1029 29.5 720 33.2 1749 30.9
Suppressed 2462 70.5 1451 66.8 3913 69.1
SR HIV testing and treatment status Last test HIV positive on ART 2199 63.0 1098 50.6 3297 58.2
Last test HIV positive but not currently on ART or with
no data on ART
358 10.3 308 14.2 666 11.8
Last test HIV negative 507 14.5 391 18.0 898 15.9
Don’t know HIV status 282 8.1 272 12.5 554 9.8
Never tested 145 4.2 102 4.7 247 4.4
ART adherence (n = 3341)* Yes 1938 87.8 967 85.4 2905 87.0
No (poor adherence) 270 12.2 166 14.6 436 13.0
Time of diagnosis† Before PopART 1286 50.3 902 64.2 2188 55.2
During PopART 940 36.8 380 27.0 1320 33.3
SR HIV+ with missing dates 331 12.9 124 8.8 455 11.5
Did not self-report HIV positive 934 765 1699
Categories
Zambia South Africa Total
N % N % N %
HIV Stigma
Any stigma† No stigma experienced 1680 65.7 1083 77.0 2763 69.7
Any stigma experienced 877 34.3 323 23.0 1200 30.3
Did not self-report HIV positive 934 765 1699
Experienced stigma in health service settings
(n = 3963)‡
Never 2442 95.5 1311 93.2 3753 94.7
At least once 115 4.5 95 6.8 210 5.3
Experienced stigma in the community (n = 3963)‡ Never 1962 76.7 1182 84.1 3144 79.3
At least once 595 23.3 224 15.9 819 20.7
Current internalized stigma (n = 3963)‡ Do not agree 2075 81.1 1255 89.3 3330 84.0
Agree 482 18.9 151 10.7 633 16.0
Perceived stigma in health service settings
(n = 1154)§
Do not agree 543 75.6 362 83.0 905 78.4
Agree 175 24.4 74 17.0 249 21.6
Perceived stigma in the community (n = 1154)§ Do not agree 237 33.0 276 63.3 513 44.5
Agree 481 67.0 160 36.7 641 55.5
(continued on next page)
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stigma in the community, and internalized stigma was more
commonly reported by those who reported experienced
stigma but was not associated with community-level
stigma measures (see Table 3 and Figure 2, Supplemental
Digital Content, http://links.lww.com/QAI/B538). Among
PC-HIV+sub participants, 67.0% of Zambians and 36.7% of
South Africans reported that they perceived stigma to be
present in communities, with lower proportions perceiving
stigma in health service settings (24.7% and 17.7% respec-
tively). Most PC-HIV+SR had disclosed their status to
someone, and a substantial minority (20.5%) of those who
reported ever taking ART said that they had hidden their
ART pills at some time (Table 2).
Viral suppression was lower in South Africa, among
men, and among younger participants (Table 3). Viral
suppression was highest among PC-HIV+ participants who
reported currently taking ART (88.3%). Viral suppression
was lower among those that did not answer questions on
experience and internalization of stigma because they SR that
they were HIV negative [adjusted risk ratio (aRR) = 0.48;
95% CI: 0.44 to 0.52], had never had an HIV test (aRR =
0.66; 95% CI: 0.59 to 0.73), or that they did not know their




Zambia South Africa Total
N % N % N %
Disclosed HIV status No 272 10.6 234 16.6 506 12.8
Yes 2285 89.4 1172 83.4 3457 87.2
Did not self-report HIV positive 934 765 1699
Have you ever hidden your ART pills?k No 1687 76.3 973 85.7 2660 79.5
Yes 524 23.7 162 14.3 686 20.5
Did not self-report HIV positive or ever start ART 1280 1036 2316
*Poor or nonadherence was defined as “respondents self-reporting that they had ever started ART but were not currently taking ART or currently taking ART but had either
stopped in the past 12 months, or missed pills in the past 7 days.”
†Time of first positive HIV test result was asked only to those who SR HIV positive.
‡Stigma items captured by PLHIV who SR HIV positive.
§Stigma items captured by PLHIV who completed the extended questionnaire (random 20% sample of the PC).
kAsked to everyone but those ever started on ART.
TABLE 3. The Association Between Sociodemographic Characteristics, ART Adherence, and SR HIV Status With Viral Suppression
Among at PC24 in 21 Communities in Zambia and South Africa (n = 5662)
Variable Categories % virally suppressed, n/N (%) aRR* (95% CI)
Country† Zambia 2462/3491 (70.5%) 1.00
South Africa 1451/2171 (66.8%) 0.93 (0.90 to 0.97)
Age group‡ 18–24 548/1105 (49.6%) 1.00
25–34 1762/2527 (69.7%) 1.41 (1.33 to 1.51)
35–44 1603/2030 (79.0%) 1.61 (1.51 to 1.71)
Sex Male 458/791 (57.9%) 1.00
Female 3455/4871 (70.9%) 1.26 (1.18 to 1.33)
ART adherence (n = 3341)§ Yes 2592/2905 (89.2%) 1.00
No (poor adherence) 328/436 (75.2%) 0.85 (0.81 to 0.90)
Self-reported HIV testing and treatment statusk Last test HIV positive on ART 2912/3297 (88.3%) 1.00
Last test HIV positive but not currently on ART or with
no data on ART
250/666 (37.5%) 0.43 (0.39 to 0.48)
Last test HIV negative 355/898 (39.5%) 0.48 (0.44 to 0.52)
Do not know HIV status 254/554 (45.8%) 0.54 (0.49 to 0.59)
Never tested 142/247 (57.5%) 0.66 (0.59 to 0.73)
Bolded, P , 0.05
*Adjusted for age group, sex, and community with robust standard errors.
†The aRR is adjusted for age group and sex with robust standard errors.
‡Overall P value for age group: P , 0.001.
§Poor or nonadherence was defined as “respondents self-reporting that they had ever started ART but were not currently taking ART,or currently taking ART but had either
stopped in the past 12 months, or missed pills in the past 7 days.”
kOverall P value for SR HIV testing and treatment status: P , 0.001.
n, number of individuals that are virally suppressed; N, total number of individuals within groups.
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status (aRR = 0.54; 95% CI: 0.49 to 0.59). Viral suppression
was also lower for those self-reporting poor adherence (aRR =
0.85; 95% CI: 0.81 to 0.90; Table 3) and for those self-
reporting hiding their ART pills, although the statistical
evidence for the latter was weak (aRR = 0.97; 95% CI:
0.94 to 1.00; Table 4).
In unadjusted and fully adjusted analyses (Table 4),
there was little evidence of an association between experi-
enced stigma in either community or health service setting
and viral suppression at PC24 among PC-HIV+SR. However,
those reporting internalized stigma were less likely to be
virally suppressed than those who did not (aRR = 0.94; 95%
CI: 0.89 to 0.98). This association was similar in all 3 arms of
the trial (see Figure 3, Supplemental Digital Content, http://
links.lww.com/QAI/B538, interaction; P = 0.72) and was also
seen when stigma was characterized as a continuous variable
(see Table 4, Supplemental Digital Content, http://links.lww.
com/QAI/B538). Those reporting internalized stigma also
reported that they were less likely to have ever started ART or
currently be taking ART and more likely to report having ever
hidden pills and to have been recently nonadherent (see Table 5,
Supplemental Digital Content, http://links.lww.com/QAI/
B538).
There was little evidence of interaction between study
arm, viral suppression, and any of the other stigma exposures
(see Table 6, Supplemental Digital Content, http://links.lww.
com/QAI/B538). In the exploratory analysis, the patterns
were similar when stigma exposures were measured at PC0 or
PC12, except that the association between internalized stigma
and viral suppression became statistically weak (see Tables
TABLE 4. The Association Between Experienced and Perceived HIV Stigma and Viral Suppression at PC24 in 21 Communities in
Zambia and South Africa
Variable Categories n/N (%) aRR* (95% CI) aRR† (95% CI)
Self-report HIV status‡ SR HIV positive 3162/3963 (79.8%) 1.00 1.00




Any stigma (n = 3963) No stigma experienced 2223/2763 (80.5%) 1.00 1.00
Any stigma experienced 939/1200 (78.3%) 0.97 (0.93 to
1.00)
0.97 (0.93 to 1.00)
Experienced stigma in health service setting
s (n = 3963)
Never 2995/3753 (79.8%) 1.00 1.00
At least once 167/210 (79.5%) 1.00 (0.93 to
1.07)
0.99 (0.93 to 1.06)
Experienced stigma in the community (n = 3963) Never 2512/3144 (79.9%) 1.00 1.00
At least once 650/819 (79.4%) 0.98 (0.94 to
1.02)
0.98 (0.94 to 1.02)
Current internalized stigma (n = 3963) Disagree 2687/3330 (80.7%) 1.00 1.00
Agree 475/633 (75.0%) 0.94 (0.89 to
0.98)
0.94 (0.89 to 0.98)
Disclosed HIV status (n = 3963) No 358/506 (70.8%) 1.00 1.00
Yes 2804/3457 (81.1%) 1.13 (1.06 to
1.20)
1.11 (1.05 to 1.18)
Did not self-report HIV positive 751/1699 (44.2%) — —
Have you ever hidden your ART pills? (n = 3963) No 2334/2660 (87.7%) 1.00 1.00
Yes 591/686 (86.2%) 0.97 (0.94 to
1.01)
0.97 (0.94 to 1.00)
Self-report HIV positive but never started
ART
237/617 (38.4%) — —
Population group receiving the extended stigma
questionnaire
Not receiving the perceived stigma
questions
3112/4508 (69.0%) 1.00 1.00
Random 20% sample of the PC 801/1154 (69.4%) 1.00 (0.96 to
1.05)
1.01 (0.97 to 1.05)
Perceived stigma in health service settings
(n = 1154)§
Do not agree 628/905 (69.4%) 1.00 1.00
Agree 173/249 (69.5%) 1.05 (0.96 to
1.15)
1.05 (0.96 to 1.15)
Perceived stigma in the community (n = 1154)§ Do not agree 352/513 (68.6%) 1.00 1.00
Agree 449/641 (70.0%) 1.03 (0.95 to
1.12)
1.01 (0.94 to 1.10)
Bolded, P , 0.05.
*Model adjusted for age group, sex, and community with robust standard errors.
†Model adjusted for age group, sex, education, marital status, time of diagnosis, and community with robust standard errors.
‡Model adjusted for age group, sex, education, marital status, and community with robust standard errors.
§Stigma items captured by PLHIV who completed the extended questionnaire (random 20% sample of the PC).
n, number of individuals that are virally suppressed; N, total number of individuals within groups.
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7–12, Supplemental Digital Content, http://links.lww.com/
QAI/B538).
At community level, there was one outlier community
with a low viral suppression rate (29.3%), with the others
ranging from 54.4% to 80.0% (Fig. 1). There was some, but
limited, variation in the average level of stigma across
communities. There was little evidence that the proportion
of PC-HIV+ who were virally suppressed in a community
was associated with any of the community-level measures of
stigma as measured among PC-HIV+SR, PC-HIV2, HWs, or
CHiPs (Fig. 1). These results were similar when community-
level stigma measures from earlier rounds of data collection
were used (see Figures 4 and 5, Supplemental Digital
Content, http://links.lww.com/QAI/B538).
DISCUSSION
At 24 months into the HPTN (071) PopART cluster-
randomized trial in 21 study communities in Zambia and
South Africa, 69.1% of the randomly selected research PC
participants living with HIV were virally suppressed. Viral
suppression was lowest among PLHIV who did not report
that they were living with HIV in the research interview.
Among self-identifying PLHIV, those who reported internal-
ized stigma were less likely to be virally suppressed than
those who did not, were also less likely to report ever or
current ART use, and were more likely to report hiding pills
or recent non-adherence to ART. Experienced stigma in the
community or health setting and perceived stigma were not
associated with poorer viral suppression. The associations
were similar across all 3 arms of the trial under different
approaches to the delivery of HIV testing and treatment. The
viral suppression rate among PLHIV was not associated with
any of the community-level measures of stigma reflected in
the responses of PLHIV, community members, or HWs.
This was a large study of a representative random
sample of PLHIV in 21 communities, with data on a valid,
biologically measured, outcome variable (viral suppression)
reflective of the cumulative success of efforts to support
PLHIV along the continuum of care, from diagnosis, to
linkage to care, to adherence to antiretroviral medication. We
used theory-based, harmonized, and validated measures of a
range of dimensions of stigma.15
Nevertheless, our study had limitations that may have
relevance to future studies on this subject. First, although we
had high response rates, we were missing data on stigma
FIGURE 1. The association between the beliefs and perceptions of PC-HIV+SR, PC-HIV, HWs, and CHiPs and levels of viral sup-
pression among 6233 laboratory-confirmed HIV-positive participants in 21 communities in South Africa and Zambia.
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among an important group: PLHIV who did not self-report
their HIV-positive status. Lack of self-report of a positive
HIV status might be because HIV-positive status was not yet
diagnosed (in which case participants would not be on ART
and would also not have had a chance to experience HIV
stigma) or because participants chose not to reveal their status
to an interviewer (in which case they may in fact be on ART,
but stigma may also be relevant to their decision not to
disclose to the interviewer). The overall impact of these
potentially different effects on the association of interest in
this article is not clear. Second, despite many years of
research into measurement of stigma and our use of best-
practice measures, stigma remains a complex and evolving
phenomenon, potentially subject to reporting biases. There-
fore, the items we included to assess stigma may not have
captured all the subtle experiences of stigma of PLHIV in our
study setting.
Four other studies have explored measures of HIV
stigma and their association with viral suppression.18–21
Among a cohort of 6448 PLHIV in care in the United States,
88% of whom were virally suppressed, a “modest but
significant” association was observed between internalized
stigma and concurrent viremia. This followed a smaller study
in the United States nested within a randomized trial of an
intervention to reduce HIV stigma among 234 African
American women in HIV care in 3 cities, in which changes
in viral load over time were associated with experiences of
stigma.19 In another US study, among 92 young Black men
who have sex with men, those who reported higher levels of
total stigma and personalized stigma were less likely to be
virally suppressed.21 These studies build on a wealth of
evidence from multiple settings that suggest that stigma is a
barrier to the continuum of care for PLHIV. Our finding of an
association between current internalized stigma and viral
suppression aligns with existing research, but it is unexpected
in suggesting that experience of stigma, perception of stigma,
and community-level stigma were not associated with viral
suppression in our study communities.
Why might we have seen this unexpected finding?
Previous reviews may have been more likely to report
findings of an association than if they did not find one with
each of the steps of the treatment cascade. Alternatively, the
context of our study may differ. In 2 arms of the study,
intensive, home-based interventions were being delivered to
test the whole community and link and initiate antiretroviral
treatment for all PLHIV, and this may explain the absence of
an effect. Levels of knowledge of HIV status were high across
all the study communities, especially in arms A and B.
Furthermore, levels of viral suppression were lower among
PLHIV who did not self-report their HIV status (and therefore
did not answer questions on HIV stigma). Ongoing efforts to
reach the undiagnosed fraction with testing remain essential.
It is hard to unpick the importance of stigma as a barrier to
reaching the undiagnosed. However, there is growing recog-
nition of the importance of HIV transmission in early
infection. Universal test and treat approaches based on annual
testing cycles may struggle to address this. Newly infected
individuals involved in concurrent partnerships, including
highly stigmatized groups such as female sex workers and
their clients, men who have sex with men, and transgender
individuals, may be particularly vulnerable. Public health
messaging that emphasizes the importance of frequent HIV
testing, and testing after potential exposure to HIV, continues
to be essential. Differentiated services, including programs
that offer testing and prevention at a more frequent rate for
stigmatized groups involved in such sexual networks will
need to overcome stigma.
HIV programs must also work toward the elimination of
HIV transmission during the period between an HIV diagnosis
and viral suppression. Linkage to care was lower among those
experiencing stigma in a universal test and treat trial in South
Africa, and linkage to care was slower among those feeling
shame about an HIV diagnosis in a case–control study nested
within the trial reported in this article.22 Post-HIV test
counseling, including with couples, is critical and must
emphasize messages that overcome the impact of stigma on
slow linkage to care. These include (1) that treatment can be
sought rapidly to improve individual health, (2) that safe sex
should be observed during the period between a diagnosis and
initiating treatment and attaining a suppressed viral load, and, (3)
counseling services and/or peer support that limits the develop-
ment of internalized stigma, supports appropriate disclosure to
foster social support, and strengthens resilience is critically
important, and PLHIV should have access to these services.
Finally, stigma can reduce treatment adherence if
participants experience mental health problems or are reluctant
to be seen at clinic or identified as living with HIV.6 Previous
research has identified a potentially strong effect of internalized
stigma on mental health and treatment decisions and
adherence.23–26 Our findings are in line with these studies. In
our qualitative work, anticipation of stigma, linked to feelings
of low worth, was an important component of narratives of
people in these communities and their decisions to initiate or
stay on treatment. In an earlier analysis, we found that SR ART
adherence was lower among those who had experienced and
internalized stigma among PLHIV who started treatment
before the PopART trial and were enrolled at PC0.27
Health services must therefore continue to strive
to minimize the effects of stigma on access to treatment.
Although there was no association in our study between health
service setting stigma and viral suppression at community level,
the pathways between such experiences and health outcomes
remain unclear. Our qualitative research highlights how critical
friendly health services are for patients.6 HWs who are
themselves living with HIV may have an important role.
Clinical treatment services must play close attention to the
mental health of patients on treatment. Although there is some
evidence that the prevalence of HIV stigma in Africa is reducing
as testing and treatment scale-up,28–30 efforts to reduce stigma
must continue at multiple levels and have the potential to
catalyze continued strengthening of HIV control efforts.
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